(AOF) – Mauna Kea Technologies announces the first 510(k) clearance from the FDA for the use of the Cellvizio in a new category of endoscopic, laparoscopic and needle procedures guided by molecular imaging. This authorization is for the use of Cellvizio in the fluorescence imaging of tissues targeted by a molecular marker, Pafolacianin, marketed as Cytalux and manufactured by On Target Laboratories, in accordance with its approved use and method of administration. .
Additionally, the authorization includes a new clinical indication for the use of Cellvizio for fluorescence imaging and visualization of ICG (indocyanine green), intravenously or interstitially, in accordance with the use and direction. the approved method of administration of the ICG. The 510(k) includes all Cellvizio Confocal Miniprobes in all authorized clinical indications.
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors in no way guarantee the absence of error and defects, even hidden ones, nor the exhaustive character or the lack of conformity for any use whatsoever of this data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember on the financial markets.